A Multi-centre, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects Who Participated in theMEA115588 or MEA115575 Trials

Mepolizumab

Number of Participants With Adverse Events (AEs) Including Both Systemic (i.e. Allergic/Immunoglobulin (Ig)E-mediated and Non-allergic) and Local Site Reactions

Number of Participants With Positive Anti-mepolizumab Binding Antibodies and Neutralizing Antibodies (NAb) at the Indicated Time Points

Annualized Rate of Exacerbations Per Year

Mean Change From Baseline in Asthma Control Questionnaire (ACQ) Score

Mean Change From Baseline in Clinic Pre-bronchodilator FEV1 Over the 52-week Treatment Period

Number of Participants Withdrawn Due to Lack of Efficacy and Adverse Events From the Study

Number of Participants Hospitalized Due to Exacerbations and Adverse Events

Number of Participants With Systemic (i.e., Allergic/IgE-mediated and Non-allergic) and Local Site Reactions

Number of Participants With Electrocardiogram (ECG) Findings at Any Time Post Baseline

Mean Change From Baseline in QT Interval Corrected by Bazett's Method (QTcB) and QT Interval Corrected by Fridericia's Method (QTcF) Values for ECG Assessed at Baseline, Week 28, Week 52 and at Follow-up Visit (Approx. 12 Weeks Post-last Dose)

Number of Participants With Maximum Change From Baseline in QTcF Interval for ECG Assessed at Any Time Post Baseline

Number of Participants With Maximum Change From Baseline in QTcB Interval for ECG Assessed at Any Time Post Baseline

Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure Assessed at Week 52

Change From Baseline in Pulse Rate Assessed at Week 52

Number of Participants With Clinical Chemistry Parameters Outside the Normal Range at Any Time Post-baseline

Number of Participants With Haematology Laboratory Parameters Outside the Normal Range at Any Time Post-baseline